FamiCord Group Named Europe’s Leading Stem Cell Bank by Life Sciences Review

Smart Cells is proud to share that our parent company, the FamiCord Group, has been awarded “Best European Stem Cell Bank 2025” by Life Sciences Review, recognising excellence, innovation and leadership in stem cell banking across Europe.

A milestone in European stem cell banking

FamiCord Group is the largest stem cell bank in Europe and the third largest in the world, providing advanced services for the collection, processing and long-term preservation of umbilical cord blood and perinatal tissues.

The Life Sciences Review award acknowledges FamiCord’s proven track record in delivering safe, clinically reliable and high-quality services, backed by international accreditations and decades of scientific expertise.

Independent experts selected FamiCord as Europe’s Leading Stem Cell Bank for its consistent performance in supporting families and healthcare professionals, ensuring every sample preserved has the potential to make a difference in future therapies.

Excellence validated by global standards

FamiCord’s success is underpinned by its commitment to quality and compliance:

• Nearly half of its laboratories are AABB-accredited (Association for the Advancement of Blood & Biotherapies). 
• The Group’s systems cover the entire process — from collection and processing to secure long-term storage and clinical application.
• All facilities operate under full national regulatory compliance and adhere to standards set by the European Group for Blood and Marrow Transplantation (EBMT).

As Dr Tomasz Baran, Chief Medical Officer of FamiCord Group and Chief Executive Officer of Smart Cells, noted:

“This recognition demonstrates our continued dedication to scientific excellence, safety and innovation — ensuring that every sample preserved today can support life-saving and regenerative therapies in the future.”

Impact through clinical innovation and global growth

FamiCord’s contribution extends well beyond storage. The Group’s pioneering work in clinical applications has already benefited almost 2,000 patients through perinatal stem-cell therapies worldwide.

The company continues to expand internationally, with the opening of its first laboratory in Dubai in 2024, which also achieved AABB accreditation. This expansion reinforces FamiCord’s commitment to making cutting-edge stem-cell preservation accessible to families across more regions.

Collaboration and research at the heart of progress

FamiCord’s leadership is also built on strong partnerships within the medical and scientific community.
Through collaborations with institutions such as the Medical University of Lublin, the Group supports clinical research into innovative treatments for conditions including cerebral palsy and autism, following internationally recognised protocols.

By maintaining rigorous scientific standards and active research involvement, FamiCord and its partner banks — including Smart Cells — are helping translate stem-cell science into real therapeutic outcomes.

What this means for Smart Cells families

As part of the FamiCord Group, Smart Cells is proud to share in this recognition. It reflects our shared values of clinical excellence, innovation, and trust — and reinforces our ongoing mission to provide families with the highest standards in cord blood and tissue banking.

This award is a testament to the dedication of our laboratory and healthcare partners who work tirelessly to ensure that every collection is performed with precision and care.

Looking ahead

The “Europe’s Leading Stem Cell Bank” award is not only a celebration of past achievements — it’s a reaffirmation of FamiCord’s and Smart Cells’ shared vision:
to make stem-cell preservation accessible, trusted and clinically valuable for families worldwide.

We remain dedicated to helping parents secure the life-saving potential of stem cells today — for the health of generations to come.

About Life Sciences Review

Life Sciences Review is a global industry publication that highlights innovation and leadership across biotechnology, healthcare and life sciences. Its annual recognition programme identifies organisations setting new benchmarks for quality, scientific advancement and clinical impact around the world.